 Patent Application Title |
Patent App Num. |
Date |
 Malaria vaccine | 20130149317 | 20130613 |
 (c) a polypeptide consisting of an amino acid sequence having 70% or more identity with an amino acid sequence of SEQ ID NO: 1, 2, or 3 and having effect for preventing falciparum malaria.
... |
| Yersinia pestis antigens, vaccine compositions, and related methods | 20130149327 | 20130613 |
 The present invention provides antigens and vaccines useful in prevention of infection by Yersinia pestis. The present invention provides pharmaceutical compositions of such antigens and/or vaccines. The present invention provides methods for the production of Y. pestis protein antigens in plants, as well as methods for their use in the treatment and/or prevention of Y. pestis infection.
... |
| Broadly protective shigella vaccine based on type iii secretion apparatus proteins | 20130149329 | 20130613 |
 Broad-based, cross-protective, O-serotype independent vaccines against Shigella and related pathogenic organisms are provided. The vaccines comprise one or more of the type III secretion (TTS) apparatus needle proteins IpaD and IpaB, and/or the IpaB cognate chaperone protein IpgC. Chimeric proteins of IpaD and IpaB, and/or IpgC are also encompassed.
... |
| Rhamnose and forssman conjugated immunogenic agents | 20130149331 | 20130613 |
 The present invention provides an immunogenic composition comprising a T-cell antigen in association with a rhamnose monosaccharide and/or Forssman disaccharide, and corresponding methods for inducing immune response. The T-cell antigen may be for example, a tumor vaccine, such as a tumor cell or one or more tumor antigens. The invention takes advantage of the naturally high titers of anti-Rhamnose and/or anti-Forssman disaccharide in humans to target vaccine compositions to antigen presenting cells.
... |
| Compositions and methods for rapid immunization against dengue virus | 20130149338 | 20130613 |
 Embodiments of the present invention report compositions and methods for vaccinating a subject against all dengue virus serotypes. In some embodiments, multiple vaccine compositions may be administered to a subject in different anatomical locations in order to induce a rapid response to all dengue virus serotypes. In certain embodiments, administration of two or more vaccine compositions to a subject against all dengue virus serotypes may include two or more routes of administration.
... |
Subscribe to updates on this page: Vaccine RSS  |
| Yeast-based vaccines as immunotherapy | 20130149340 | 20130613 |
| Compositions and methods for treating and/or preventing a variety of diseases and conditions that are amenable to immunotherapy and, in one particular embodiment, compositions and methods for treating and/or preventing cancer in an animal are described. Specifically improvements related to the use of a yeast-based vaccine comprising a yeast vehicle and an antigen that is selected to elicit an antigen-specific cellular and humoral immune response in an animal, for use in prophylactic and/or therapeutic vaccination and the prevention and/or treatment of a variety of diseases and conditions are disclosed.
... |
| Porous degradable polyelectrolyte microspheres as vaccine vector | 20130149357 | 20130613 |
| The present invention discloses a composition comprising a polyelectrolyte complex and a polyol, characterised in that said polyol is in amorphous form. Optionally, the composition further comprises one or more drugs, wherein each drug has a molecular weight of at least 1000 Dalton. Said compositions are obtainable by spray-drying. The compositions may be prepared in particle form and as a suspension of particles. Pharmaceutical compositions are also provided for use in extracellular drug delivery. Pharmaceutical compositions are also provided that exhibit a controlled dual drug release.
... |
| Vaccine composition based on sticholysin encapsulated into liposomes | 20130149376 | 20130613 |
| The disclosed compositions allow modulation of CTL-specific immune response against one or several antigens co-encapsulated into toxin-containing liposomes. The vaccinal vehicle of the present invention shows advantages over others disclosed by the previous art due to the robustness and functionality of the induced immune response as well as its immunomodulating properties.
... |
| Thermal inactivation of rotavirus | 20130149384 | 20130613 |
| Methods of thermally inactivating a rotavirus are provided according to the present invention which include exposing the rotavirus to a temperature in the range of about 50° C.-80° C., inclusive, for an incubation time sufficient to render the rotavirus incapable of replication or infection. The thermally inactivated rotavirus is antigenic and retains a substantially intact rotavirus particle structure. Vaccine compositions and methods of vaccinating a subject against rotavirus are provided which include generation and use of thermally inactivated rotavirus.
... |
| Potency test for vaccine formulations | 20130149726 | 20130613 |
| The invention relates to certain methods for the determination of an antigen content of a first antigen in a mixture comprising two or more antigens. The invention also relates to a potency test for an antigen in a combination vaccine. The method allows the determination of the antigen content in a mixture additionally comprising antibodies that are capable of binding with the antigen.
... |
| Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation | 20130142818 | 20130606 |
| The present invention is directed to a polymeric carrier cargo complex, comprising as a cargo at least one nucleic acid (molecule) and disulfide-crosslinked cationic components as a (preferably non-toxic and non-immunogenic) polymeric carrier. The inventive polymeric carrier cargo complex allows for both efficient transfection of nucleic acids into cells in vivo and in vitro and/or for induction of an (innate and/or adaptive) immune response, preferably dependent on the nucleic acid to be transported as a cargo. The present invention also provides, pharmaceutical compositions, particularly vaccines and adjuvants, comprising the inventive polymeric carrier cargo complex and optionally an antigen, as well as the use of such the inventive polymeric carrier cargo complex and optionally an antigen for transfecting a cell, a tissue or an organism, for (gene-)therapeutic... |
| Method of preventing and treating inflammatory diseases and disorders with abscisic acid | 20130142825 | 20130606 |
| The present invention relates to the use of a therapeutically effective amount of abscisic acid (ABA) or its analogs to treat or prevent inflammation induced by exposure to lipopolysaccharide (LPS) or respiratory inflammation. The invention also relates to methods and composition for enhancing vaccine efficacy using ABA.
... |
| Compositions and methods for the detection of hiv-1/hiv-2 infection | 20130143202 | 20130606 |
| This invention relates to compositions and methods or the detection of immunodeficiency virus infection, especially immunodeficiency virus-1 (HIV-1) infection. The invention particularly concerns compositions and methods that may be used in HIV vaccine recipients whose sera may contain vaccine-generated anti-HIV-1 antibodies.
... |
Subscribe to updates on this page: Vaccine RSS |
| Streptococcus pyogenes antigens and corresponding dna fragments | 20130136760 | 20130530 |
| The present invention relates to antigens, more particularly antigenS of Streptococcus pyogenes (also called group A Streptococcus (GAS)) bacterial pathogen which are useful as vaccine component for therapy and/or prophylaxis.
... |
| Compositions, methods and uses for poxvirus elements in vaccine constructs | 20130136767 | 20130530 |
| Embodiments of the present invention generally disclose methods, compositions and uses for generating and expressing poxvirus constructs. In some embodiments, constructs may contain an influenza virus gene segment. In certain embodiments, methods generally relate to making and using compositions of constructs including, but not limited to, poxvirus vaccine compositions. In other embodiments, vaccine compositions are reported of use in a subject.
... |
| Point of care immunization testing system | 20130137607 | 20130530 |
| A point of care immunization system based upon microfluidics and micro-titration technologies to rapidly test a patient in order to ascertain an immunization profile so that vaccinations can be administered to address identified gaps. A point of care system comprised of uniquely shaped and color distinguishing sample and test cartridges, with said test cartridges configured to meet healthcare requirements of national governing bodies. A point of care system including an easy access vaccine storage device with indicators to provide data on viability of stored vaccines.
... |
| B-cell stimulating fusion proteins of an antigen with baff or april | 20130139274 | 20130530 |
| The invention relates to the fields of molecular biology, medicine, virology and vaccine development. Because the different forms of the presently available vaccines all have their specific drawbacks, there is a need for alternative vaccine strategies. The current invention provides means and methods for such alternative vaccine strategies.
... |
| Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein | 20130129754 | 20130523 |
| The present application describes a coding nucleic acid sequence, particularly a messenger RNA (mRNA), comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal and the use thereof for increasing the expression of an encoded protein. It also discloses its use for the preparation of a pharmaceutical composition, especially a vaccine e.g. for the use in the treatment of tumours and cancer diseases, cardiovascular diseases, infectious diseases, autoimmune diseases or genetic diseases, or in gene therapy. The present invention further describes an in vitro transcription method, in vitro methods for increasing the expression of a protein using the nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal and an ex vivo and in... |
| Novel immunoadjuvant compounds and uses thereof | 20130129756 | 20130523 |
| The present invention relates to a cyclic beta glucan compound for use as an immuno adjuvant and vaccine composition comprising thereof. These novel adjuvant compounds represent in particular a new class of dendritic cell activating molecules.
... |
| Influenza virus vaccine and uses thereof | 20130129761 | 20130523 |
| Provided herein are influenza hemagglutinin stem domain polypeptides, compositions comprising the same, vaccines comprising the same and methods of their use.
... |
| Marker vaccine for classical swine fever | 20130129762 | 20130523 |
| The invention relates to a marker vaccine for prophylactic treatment of classical swine fever comprising modified live attenuated classical swine fever virus. The viral amino acid sequence of the TAV-epitope of the E2 protein comprises a different sequence from that of a wild-type classical swine fever virus. The invention relates to pharmaceutical compositions of the marker vaccine. The invention also relates to a method of manufacturing marker vaccines for prevention of classical swine fever using selective antibody pressure.
... |
| Influenza vaccine | 20130129770 | 20130523 |
| The present invention relates to a composition comprising at least one ISCOM complex and at least one ectodomain from at least one hemagglutinin (HA) domain and at least one ectodomain from at least one neuraminidase (NA) domain from one or more influenza virus, wherein the extodomains represent ectodomains isolated from the influenza virus. The invention also regards a kit. The composition may be used as an immune stimulating medicine, immune modulating pharmaceutical or a vaccine e.g. against influenza for vertebrates, e.g. birds and mammals.
... |
| Broad spectrum vaccine against typhoidal and non-typhoidal salmonella disease | 20130129776 | 20130523 |
| The present invention is drawn to multivalent Salmonella enterica serovar conjugate vaccines comprising conjugates of S. Typhimurium, S. Enteritidis, S. Choleraesuis, S. Typhi, S. Paratyphi A and optionally S. Paratyphi B, wherein the conjugates comprise a hapten antigen and a carrier antigen, wherein at least one of the hapten antigens or carrier antigens is characteristic of the Salmonella enterica serovar. The present invention also provides Salmonella enterica serovar reagent strains to produce the multivalent conjugate vaccines and attenuated Salmonella enterica serovars for use as vaccines.
... |
| Conjugates of plasmodium falciparum surface proteins as malaria vaccines | 20130129777 | 20130523 |
| Conjugates of ookinete surface protein Pfs25 are provided that are efficacious as vaccines against Plasmodium falciparum, the most severe form of malaria. Conjugates of ookinete surface protein Pvs25 for use as a vaccine against Plasmodium vivax are also provided. Methods for preparing the conjugates, which comprise the ookinete surface protein bound onto itself or onto another protein by a linking group, are also provided.
... |
| Viral particles derived from an enveloped virus | 20130129778 | 20130523 |
| The invention relates to generating a vaccine based on immunogens from viral particles that initially have replication competency but are then inactivated by chemical, biophysical or other methods. The components of this vaccine may be a non-HIV enveloped virus that contains and expresses a gene related to the HIV Envelope gene such that the Envelope protein is expressed on the surface of viral particles. These viral particles may be further treated to reduce their replication competency. The vaccine further may contain components to improve its immunogenicity, tolerability, stability and ease of manufacture.
... |
| Cattle reproductive disease vaccines | 20130129779 | 20130523 |
| The present invention relates to combination vaccines and methods for treating or preventing diseases or disorders in an animal caused by infection by Bovine Viral Diarrhea Virus (BVDV) Types 1 and 2, Bovine Herpes Virus Type-1 (BHV-1), Bovine Respiratory Syncytial Virus (BRSV), Parainfluenza Virus (PI3), Campylobacter fetus, Leptospira canicola, Leptospira grippotyphosa, Leptospira hardj-prajitno, Leptospira icterohaemmorrhagiae, Leptospira hardjo-bovis and Leptospira pomona by administering to the animal an effective amount of a combination vaccine. The combination vaccine can be a whole or partial cell inactivated or modified live preparation.
... |
| Methods and compositions for intranasal delivery | 20130129781 | 20130523 |
| Provided herein are methods for generating dry vaccine powder formulations. Dry vaccine powder formulations can be used for intranasal delivery. Also provided are methods for stimulating local mucosal and systemic immunity by intranasal vaccine delivery.
... |
| Hydrophilic filtration during manufacture of vaccine adjuvants | 20130129786 | 20130523 |
| An improved method for the manufacture of an oil-in-water emulsion involves three procedures: (i) preparation of a preliminary emulsion; (ii) micro fluidization of the preliminary emulsion to reduce its droplet size; and (iii) filtration of the microfluidized emulsion through a hydrophilic membrane. The emulsions are useful as vaccine adjuvants.
... |
| Device, method, and system for neural modulation as vaccine adjuvant in a vertebrate subject | 20130131435 | 20130523 |
| A method for enhancing an immune response in a vertebrate subject is described. The method includes providing at least one energy stimulus configured to modulate one or more nervous system components of the vertebrate subject, and administering one or more immunogen to the vertebrate subject, wherein the at least one energy stimulus and the one or more immunogen are provided in a combination and in a temporal sequence sufficient to enhance an immune response in the vertebrate subject.
... |
| Method of rapidly producing improved vaccines for animals | 20130122025 | 20130516 |
| A method of quickly producing a vaccine for a biotype of pathogenic microorganism is described, where a nucleic acid molecule or fragment thereof is obtained from a biological sample from an animal exposed to the microorganism, a protective molecule is prepared based on the nucleic acid molecule of interest or fragment thereof, and administered to an animal which has been or is as risk of being exposed to the microorganism. A protective response to the biotype of the microorganism is obtained in the animal.
... |
| Papilloma virus-like particles, fusion proteins as well as processes for their production | 20110015376 | 20110120 |
| The invention relates to the recombinant production of proteins as well as VLPs which are suitable as a vaccine for therapeutic and prophylactic vaccination. The invention also relates to processes for the production and purification of recombinant papilloma virus proteins and fusion proteins.
... |
| Vaccine composition containing synthetic adjuvant | 20110014274 | 20110120 |
| Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.
... |
| Method for adjuvanting lipopolysaccharide (lps) of gram-negative bacteria | 20110014272 | 20110120 |
| The subject of the invention is a method for adjuvanting LPS of a Gram-negative bacterium, according to which LPS or LPS liposomes (LPS formulated in liposomes) is (are) mixed with the lipidated human-transferrin receptor subunit B (TbpB protein) of Neisseria meningitidis or a lipidated fragment thereof; or (ii) LPS and the lipidated TbpB of N. meningitidis or a lipidated fragment thereof are formulated together in liposomes; or (iii) LPS is conjugated with the lipidated TbpB of N. meningitidis or a lipidated fragment thereof; in order to obtain a preparation which does not contain OMVs and which is capable of inducing, after administration to a mammal, an anti-LPS immune response which is improved by comparison with the anti-LPS immune response observed after administration of the corresponding preparation... |
| Therapeutic cancer antigens | 20110014241 | 20110120 |
| The present invention relates to cells, pharmaceutical compositions, tumor vaccines, kits and methods for inhibiting cell proliferation or tumor growth in a mammal, specifically, the invention relates to cells that express a tumor-associated tumor antigen.
... |
| Promoters for expression in modified vaccinia virus ankara | 20110014242 | 20110120 |
| The invention concerns promoters, in particular for the expression of genes and/or coding sequences in vaccinia viruses such as Modified vaccinia virus Ankara (MVA). The invention further concerns expression cassettes comprising said promoter, vectors comprising said expression cassettes as well as pharmaceutical compositions and vaccines.
... |
| Preparation of vaccines using photosensitizer and light | 20110014239 | 20110120 |
| Methods are provided for treating a vaccine containing infectious particles which may be viral, bacterial, and/or cellular in nature. Preferred methods include the steps of adding an effective, non-toxic amount of an endogenous photosensitizer to the fluid and exposing the fluid to photoradiation sufficient to inactivate the infectious particles but not enough to damage the antigenic characteristics of the infectious particles.
... |
| Vaccine for protection against haemophilus parasuis serotype 4 in piglets | 20110014237 | 20110120 |
| The present invention pertains to the use of Haemophilus parasuis serotype 5 bacteria in the manufacture of a vaccine for administration to a pregnant sow or gilt, to protect a piglet through the intake of colostrum of the said sow or gilt after she has farrowed, against a disorder arising from Haemophilus parasuis serotype 4 bacteria. The invention also pertains to Haemophilus parasuis serotype 5 bacteria for use in the manufacture of such a vaccine.
... |
| Therapeutic and vaccine polyelectrolyte nanoparticle compositions | 20110014235 | 20110120 |
| Polyelectrolyte nanoparticle compositions for biomedical applications are provided comprising at least two carrier domains comprising multivalent ionic domains and an agent exhibiting biological activity when contained within the nanoparticle or on the nanoparticle surface. The multivalent ionic domains may be contained in two separate molecules or in separate but linked domains of a single molecule. The nanoparticle optionally can further comprise an exposed targeting ligand and/or protective surface. The nanoparticle can be contacted to cells or administered directly to an animal for biomedical applications including therapeutics and immune response. The nanoparticle may alternatively be comprised of a carrier material capable of delivering various medically important antigens as vaccine.
... |
| Psoralen-inactivated viral vaccine and method of preparation | 20110014233 | 20110120 |
| A method to prepare inactivate viral vaccine by exposing the virus to a predetermined concentration of an inactivating psoralen, and a preselected intensity of ultraviolet radiation for a time period sufficiently long to render the virus non-infectious but less than that which would result in degradation of its antigenic characteristics.
... |
| Chimeric foot and mouth disease viruses | 20110014232 | 20110120 |
| Foot and mouth disease (FMD) viruses which are able to grow on BHK-21 cells in suspension are described herein. The new viruses are recombinant chimeric viruses formed by replacing the outer capsid coding region of a first FMDV strain, which has previously been shown to be an effective vaccine strain, with the outer capsid coding region of a second FMDV strain. The outer capsid coding region of the second FMDV strain is also modified to introduce a heparan sulphate proteoglycan (HSPG) binding site. The chimeric viruses are then used as seed viruses in the production of inactivated vaccine antigens which have been tailored for specific outbreak situations or locality. The invention also relates to the product of expression of the chimeric FMD viruses and to uses... |
| preparation of influenza virus vaccine antigens | 20110014230 | 20110120 |
| A number of improvements for preparing vaccine antigens from disintegrated influenza viruses are disclosed. A splitting step can be followed by detergent exchange. Splitting can take place in the presence of a buffer with a higher ionic strength and/or in the presence of phosphate buffer.
... |
| Il23 modified viral vector for recombinant vaccines and tumor treatment | 20110014228 | 20110120 |
| The present invention relates to recombinant replicable viral vectors and viruses which are modified with IL23. This IL23 modified virus is highly immunogenic and attenuated for neurotropic pathology found in the wild type viruses. These viruses and vectors can be used for treatment of a variety of cancers and for vaccination against many viral, bacterial, or parasitic diseases.
... |
| high throughput protein interaction assay | 20110014226 | 20110120 |
| A method to identify small molecules useful as therapeutics and/or vaccines to prevent, alleviate or ameliorate a pathogenic infection or an autoimmune disorder. The method can be used to screen small molecule test compounds for the ability to disrupt particular antigen-antibody interactions of interest. In one embodiment, the antigen is a pathogen-derived antigen and the antibody decreases or inhibits virulence of the pathogen when bound to the antigen (e.g., a neutralizing antibody, antibody with serum bactericidal activity, etc.). In another embodiment, the antigen is a self-antigen (autoantigen) and the antibody is an autoantibody that is known to be associated with a pathological condition (e.g., autoimmune disorder). Compounds that bind to the antigen or antibody disrupt binding can be used as therapeutics to decrease or inhibit the... |
| Cross-reactive determinants and methods for their identification | 20110014225 | 20110120 |
| Compositions and methods for determining immunologically cross-reactive molecules comprising a cross-reactive antigenic determinant are provided, in particular for determining proteins comprising cross-reactive antigenic determinants, in particular for determining proteins that are cross-reactive based on serological screens using sequential immunological challenges to an animal, including determining cross-reactive H. parasuis proteins. Also provided are compositions, vaccines, and kits using the molecules for diagnostics and methods for preventing or treating a disease, disorder, condition, or symptoms thereof associated with infectious agents, in particular infectious microorganisms, in particular for preventing or treating a disease, disorder, condition, or symptom thereof associated with H. parasuis infection.
... |
| Multimeric proteins able to induce an antibody response against the beta-amyloid and use thereof | 20110014223 | 20110120 |
| The present invention relates to the fields of molecular biology, immunology and medicine. Peptide sequences that belong to the beta amyloid peptide are exposed on the surface of a multimeric structure derived from the E2 component of alpha keto acid dehydrogenase. The molecules are useful for the production of vaccines for the treatment and/or prevention of Alzheimer's disease.
... |
| Stereoisomer peptides and their polymer conjugates for hiv disease | 20110014222 | 20110120 |
| The invention relates to a library of 298 peptides useful for formulating a novel therapeutic HIV vaccine. The peptide sequences were selected on the basis of calibration of molecular structure properties of HIV-1 or host cell proteins. A mixture of D- and L-amino acids or all D-amino acids are used to synthesize the stereoisomer peptides for the purpose of increasing their stability. The peptides are expected to have the ability to potently inhibit functioning of proteins important for HIV infection. A plural of the peptides are conjugated together with a biocompatible polymer, preferably HPMA to further increase stability and solubility, decrease drug toxicity, and potentially evade multidrug resistance and exert cooperative effect, since some peptides are the ligands for host proteins such as integrin, trombospondin, VEGFR... |
| Hiv combination vaccine and prime boost | 20110014221 | 20110120 |
| Provided is a novel, combination prime-boost vaccine against HIV/AIDS that induces long-lasting humoral, cell-mediated and mucosal immune responses against HIV.
... |
| Human respiratory syncytial virus (rsv) vaccine | 20110014220 | 20110120 |
| The present invention relates to a vaccine composition against the infection of human respiratory syncytial virus (RSV) comprising a replication-defective recombinant adenovirus carrying a nucleotide sequence encoding the F protein of RSV or fragment thereof. A method of preventing RSV infection-related diseases using the vaccine composition of the present invention is also provided.
... |
| Carbon nanotube compositions and methods of use thereof | 20110014217 | 20110120 |
| Carbon nanotube (CNT)-based compositions for activating cellular immune responses are provided. The CNTs function as high surface area scaffolds for the attachment of T cell ligands and/or antigens. The CNT compositions function as artificial antigen-presenting cells (aAPCs) or as modular vaccines. The disclosed CNT aAPCs are efficient at activating T cells and may be used to activate T cells ex vivo or in vivo for adoptive or active immunotherapy.
... |
| Chlamydia vaccine | 20110014210 | 20110120 |
| Compositions and methods for the treatment of Chlamydial infection are disclosed. The compositions provided include polypeptides that contain at least one antigenic portion of a Chlamydia antigen and DNA sequences encoding such polypeptides. Pharmaceutical compositions, vaccines and diagnostic kits are also disclosed.
... |
| Recombinant hcv e2 glycoprotein | 20110014209 | 20110120 |
| The invention provides modified hepatitis C virus (HCV) E2 glycoproteins comprising the HCV-E2 receptor-binding domain (RBD) including the HVR1, HVR2 and igVR variable regions wherein in at least one of said variable regions at least a part of the variable region is replaced with a flexible linker sequence. The invention also provides vaccine compositions comprising the modified glycoproteins as well as methods of use thereof.
... |
| Monoclonal antibodies capable of reacting with a plurality of influenza virus a subtypes | 20110014187 | 20110120 |
| Monoclonal antibodies directed against the influenza A virus are described, which have the advantageous and unpredicted property of being able to bind a plurality of subtypes of the influenza A virus. One preferred embodiment is the antibody designated as Fab28, which displays a neutralizing activity against a plurality of subtypes of the influenza A virus. Anti-idiotype antibodies directed against the monoclonal antibodies of the invention, immunogenic or vaccine compositions comprising the monoclonal antibodies of the invention are also described, as well as therapeutic, prophylactic and diagnostic applications for the monoclonal antibodies of the invention. The monoclonal antibodies of the invention can also be used for testing antibody preparations to be used as vaccines.
... |
| Production of homogeneous cell line highly permissive to porcine circovirus type 2 (pcv2) infection | 20110008871 | 20110113 |
| Continuous cell lines that are highly permissive to infection by porcine circovirus type 2 (“PCV2”) are described. PCV2 is the causal agent of post-weaning multi-systemic wasting syndrome (“PMWS”) in pigs. PMWS has emerged as a major disease that poses a significant threat to the economics of global swine industry. The highly permissive cell lines of this invention provide efficient and reliable sources of PCV2 for use in development of vaccines, therapies and diagnostic agents for PMWS.
... |
| Chimeric varicella zoster virus virus-like particles | 20110008838 | 20110113 |
| The present invention discloses novel chimeric Varicella Zoster Virus (VZV) virus-like particles (VLPs) comprising chimeric VZV glycoproteins. The invention also discloses vaccine formulations of the chimeric VZV-VLPs and methods of inducing an immune response in subjects.
... |
| Promoters for expression in modified vaccinia virus ankara | 20110008792 | 20110113 |
| The invention concerns promoters, in particular for the expression of genes and/or coding sequences in vaccinia viruses such as Modified vaccinia virus Ankara (MVA). The invention further concerns expression cassettes comprising said promoter, vectors comprising said expression cassettes as well as pharmaceutical compositions and vaccines.
... |
| Vaccine against streptococcus pneumoniae | 20110008419 | 20110113 |
| The present invention relates to the field of bacterial polysaccharide antigen vaccines. In particular, the present invention relates to vaccines comprising a pneumococcal polysaccharide antigen, typically a pneumococcal polysaccharide conjugate antigen, formulated with a protein antigen from Streptococcus pneumoniae selected from the group consisting of PhtA, PhtD, PhtB, PhtE, SpsA, LytB, LytC, LytA, Sp125, Sp101, Sp128, Sp130 and Sp133, and optionally a Th1-inducing adjuvant
... |
| Method for synthesizing conformationally constrained peptides, peptidomimetics and the use thereof as synthetic vaccines | 20110008414 | 20110113 |
| The present invention relates to methods for synthesizing conformationally constrained peptides and cyclic peptidomimetics obtainable by these methods which are conformationally constrained due an internal cross-link. This cross-link is formed between the side chain of an amino acid residue or analog and a (2S, 4S)4-functionalized proline residue. The invention further relates to the use of (2S, 4S)-4-functionalized proline residues as building units in the synthesis of such peptidomimetics and to the use thereof as antigens, alone or in combination with suitable immunopotentiating delivery systems, for example immunopotentiating reconstituted influenza virosomes to elicit an immune response in a mammal. Moreover, the invention also relates to pharmaceutical compositions containing the same.
... |
| Vaccine targets and delivery systems for cryptosporidium | 20110008392 | 20110113 |
| Compositions comprising the Cryptosporidium sporozoite antigens such as SRK (‘similar to riken’), CP15 and profilin are used in vaccines against the protozoan parasite Cryptosporidim.
... |
| Vaccine composition and immunization method | 20110008391 | 20110113 |
| The present invention refers to the recombinant vaccine against canine visceral leishmaniasis containing the recombinant A2 protein and saponin, as an adjuvant, allowing the distinction between vaccinated and infected animals through conventional ELISA or immunofluorescence tests that employ antigens of promastigote forms of Leishmania.
... |
| Recombinant attenuated clostridium organisms and vaccine | 20110008389 | 20110113 |
| The present invention discloses attenuated Clostridium perfringens organisms that express a substantially nontoxic alpha-toxin. The expressed alpha-toxin is a deletion mutein that relative to the alpha-toxin of the mature alpha-toxin of Clostridium perfringens strain 13, is missing at least nine consecutive amino acid residues including His68. The present invention also discloses attenuated organisms that encode the muteins, as well as the use of such attenuated organisms as vaccines.
... |
| Wt1 modified peptide | 20090325886 | 20091231 |
| The present invention discloses a cancer antigen peptide comprising the following amino acid sequence: Cys Tyr Thr Trp Asn Gln Met Asn Leu (Sequence ID No. 3), a cancer vaccine having this for its active ingredient, and a DNA vaccine having for its active ingredient DNA that codes for this peptide.
... |
| Pro-apoptotic bacteria and compositions for delivery and expression of antigens | 20090325298 | 20091231 |
| Whole-cell vaccines and methods for enhancing the immunogenicity of cellular microorganisms for use in producing protective immune responses in vertebrate hosts subsequently exposed to pathogenic bacteria or for use as vectors to express exogenous antigens and induce responses against other infectious agents or cancer cells. The present invention involves an additional method of enhancing antigen presentation by intracellular bacteria in a manner that improves vaccine efficacy. After identifying an enzyme that has an anti-apoptotic effect upon host cells infected by an intracellular microbe, the activity of the enzyme produced by the intracellular microbe is reduced by expressing a mutant copy of the enzyme, thereby modifying the microbe so that it increases immunogenicity.
... |
| Diagnostic and therapeutic application of ctl and nk functionally selected cells | 20090325213 | 20091231 |
| The invention proposes a novel therapeutic and diagnostic methodology based on the use of effector cells (for example CTL and NK cells) selected for being able to induce lysis in target cells. In particular, the invention teaches how to select strains of effector cells of the immune system according to their lytic properties. It also teaches how diagnostic procedures for checking the activity of therapeutic vaccines can be improved with respect to what shown. Finally, it shows how cell therapies used at present can be improved by using this approach.
... |
| Detection and distinguishing infections bursal disease virus (ibdv) strains by molecular biology method | 20090325149 | 20091231 |
| The present invention relates to a novel method to detect and differentiate different strains of infectious bursal disease virus (IBDV) in a chicken and other bird sample. RNA was obtained from said samples by using a pair of primer (Primer FVVC & RVVC) in a reverse transcriptase-polymerase chain reaction. Two different primer combinations (Primer IF & IVIR) and (Primer IF & RCLA) and real-time polymerase chain reaction conditions were designed and optimized for rapid differentiation of very virulent and vaccine strains of IBDV based on detection of signatory threshold cycle (Ct) and melting temperature (Tm) values.
... |
| Bead array reader based-hemagglutination and hemagglutination inhibition assay | 20090325148 | 20091231 |
| Hemagglutination assays and hemagglutination inhibition assays were introduced in medical and virology practice more than 60 years ago. Since then, these assays have become important tools for measuring concentrations and strengths of viral cultures, the efficacy of the anti-viral immunization, and for studying the neutralizing capacity of virus-specific antibodies. The present invention comprises an improved hemagglutination inhibition assay (HAI), with at least about a 10-fold increase in sensitivity versus the traditional the HAI, to provide more accurate measurements of components in, for example, fluids from the in vitro MIMIC® system when assessing the effects of anti-viral vaccines (e.g., for seasonal influenza).
... |
| Method for synthesizing conformationally constrained peptides, peptidomimetics and the use thereof as synthetic vaccines | 20090324707 | 20091231 |
| The present invention relates to methods for synthesizing conformationally constrained peptides and cyclic peptidomimetics obtainable by these methods which are conformationally constrained due an internal cross-link. This cross-link is formed between the side chain of an amino acid residue or analog and a (2S, 4S)4-functionalized proline residue. The invention further relates to the use of (2S, 4S)-4-functionalized proline residues as building units in the synthesis of such peptidomimetics and to the use thereof as antigens, alone or in combination with suitable immunopotentiating delivery systems, for example immunopotentiating reconstituted influenza virosomes to elicit an immune response in a mammal. Moreover, the invention also relates to pharmaceutical compositions containing the same.
... |
| Leishmania vaccine using sand fly salivary immunogen | 20090324649 | 20091231 |
| The present invention provides vectors that contain and express in vivo or in vitro sand fly Lu. longipalpis salivary antigens that elicit an immune response in animal or human against Leishmania, vaccine compositions comprising said vectors and/or Lu. longipalpis salivary polypeptides, methods of vaccination against Leishmania, and kits for use with such methods and compositions.
... |
| Vaccine for edwardsiella disease and streptococcal disease in fish | 20090324648 | 20091231 |
| Disclosed is a vaccine for edwardsiellosis and streptococcosis in a fish. Specifically, disclosed is a vaccine for edwardsiellosis in a fish, which comprises inactivated cells of (A) an Edwardsiella tarda strain derived from the target fish, and inactivated cells of (B) an Edwardsiella tarda strain derived from a fish other than the target fish, wherein, when the strain (A) is a typical Edwardsiella tarda strain, the strain (B) is an atypical Edwardsiella tarda strain, whereas when the strain (A) is an atypical Edwardsiella tarda strain, the strain (B) is a typical Edwardsiella tarda strain. Also specifically disclosed is a vaccine for edwardsiellosis and/or streptococcosis in a fish, which comprises the components mentioned above and inactivated cells of (C) Streptococcus iniae and/or Streptococcus parauberis.
... |
| Production of vaccines | 20090324645 | 20091231 |
| Means and methods for producing mammalian viruses, the method comprising infecting a culture of immortalized human cells with a virus, incubating the culture infected with virus to propagate the virus under conditions that permit growth of the virus, and to form a virus-containing medium, and removing the virus-containing medium. The viruses can be harvested and be used for the production of vaccines. Advantages include that human cells of the present invention can be cultured under defined serum-free conditions and the cells show improved capability for propagating virus. Methods are provided for producing, in cultured human cells, influenza virus and vaccines derived thereof. This method eliminates the necessity of using whole chicken embryos for the production of Influenza vaccines. The method also provides for the continuous or... |
| Chimeric vaccine antigens against the avian influenza virus | 20090324644 | 20091231 |
| The present invention describes chimeric vaccine antigens against the avian influenza virus (AIV). Said vaccine antigens are based on viral subunits that are coupled to protein molecules that stimulate not only the cellular but also the humoral immune system. The chimeric antigens may be produced in expression systems that guarantee correct three-dimensional folding of the chimeric molecules that constitute the basis of the present invention. The vaccine compositions that contain said chimeric antigens induce a potent, early immune response both in birds and in vaccinated mammals, stimulating high haemagglutinin-inhibiting antibody titres and a potent specific cellular response against the viral antigen. The chimeric antigens, and also the resulting vaccine compositions, are applicable to the field of human and animal health as vaccines for preventive use.
... |
| Novel adjuvant compositions | 20090324641 | 20091231 |
| This invention relates to adjuvant formulations comprising various combinations of triterpenoids, sterols, immunomodulators, polymers, and Th2 stimulators; methods for making the adjuvant compositions; and the use of the adjuvant formulations in immunogenic and vaccine compositions with different antigens. This invention further relates to the use of the formulations in the treatment of animals.
... |
| Neuraminidase-deficient live influenza vaccines | 20090324640 | 20091231 |
| Attenuated, neuraminidase deficient influenza virus, and compositions and methods to prepare that virus, are provided.
... |
| Live bacterial vaccine | 20090324638 | 20091231 |
| The present invention relates, e.g., to a Lactobacillus bacterium, which (1) expresses a recombinant polypeptide containing a lipoprotein signal sequence from the OspA protein of Borrelia burgdorferi, or an active variant of the leader sequence, operably linked to one or more heterologous polypeptide(s) of interest and/or (2) which comprises an expressible polynucleotide encoding a recombinant polypeptide, wherein the polynucleotide encodes a lipoprotein signal from the OspA protein of Borrelia burgdorferi, or an active variant thereof, which is operably linked to one or more heterologous polypeptide(s) of interest. In one embodiment, the heterologous polypeptide is from Yersinia pestis, the etiologic agent of plague. In another embodiment, the heterologous polypeptide is from Borrelia burgdorferi, the etiologic agent of Lyme disease. Also described are immunogenic compositions, such as live... |
| Trypanosoma antigens, vaccine compositions, and related methods | 20090324634 | 20091231 |
| The present invention relates to the intersection of the fields of immunology and protein engineering, and particularly to antigens and vaccines useful in prevention of infection by Trypanosoma protozoa. Provided are recombinant protein antigens, compositions, and methods for the production and use of such antigens and vaccine compositions.
... |
| Polyvalent vaccine | 20090324631 | 20091231 |
| The present invention relates, in general, to an immunogenic composition (e.g., a vaccine) and, in particular, to a polyvalent immunogenic composition, such as a polyvalent HIV vaccine, and to methods of using same. The invention further relates to methods that use a genetic algorithm to create sets of polyvalent antigens suitable for use, for example, in vaccination strategies.
... |
| Compounds useful in the diagnosis and treatment of malaria | 20090324628 | 20091231 |
| The present invention relates to nucleic acid molecules related to the PFD1235w/MAL7P1.1, PF11_0008, and PF13_0003 gene families as well as amino acid sequences encoded by such nucleic acid molecules with respect to their role in mediating adhesion of infected red blood cells to endothelial cells, which is characteristic for the pathogenesis of severe malaria (SM). Accordingly, the invention provides pharmaceutical compositions and vaccines, hereunder nucleotide-based vaccines comprising compounds that are related to VAR4, VAR5, and/or VAR6 polypeptides and PFD1235w/MAL7P1.1 PF11_0008, and/or PF13_0003 nucleic acid molecules. The invention further relates to the use of these compounds as medicaments and for the manufacture of compositions, such as immunogenic compositions. In addition, the invention relates to methods of treatment and prevention of severe malaria wherein these methods are based... |
| Antibody vaccine conjugates and uses therefor | 20090324622 | 20091231 |
| The present invention provides novel antibody vaccine conjugates and methods of using the same to induce a cytotoxic T cell (CTL) response. In a particular, embodiment, the vaccine conjugate includes a human chorionic gonadotropin beta subunit (βhCG) antigen linked to an anti-mannose receptor (MR) antibody.
... |
| Nucleic acid of formula (i): gixmgn, or (ii): cixmcn, in particular as an immune-stimulating agent/adjuvant | 20090324584 | 20091231 |
| The present invention relates to a nucleic acid of the general formula (I): GlXmGn, or (II): ClXmCn, which may be modified by a lipid. The nucleic acid of the invention acts as an immune-stimulating agent inducing the innate immune response. The invention relates further to a pharmaceutical composition (in a first embodiment), each containing an immune-stimulating agent according to the invention in combination with a pharmaceutically active carrier/vehicle (and, optionally, further auxiliary substances, additives and/or further adjuvants). In another embodiment, the inventive nucleic acid is combined with at least one pharmaceutically active component, a pharmaceutically acceptable carrier/vehicle (and, optionally, further auxiliary substances, additives and/or further adjuvants). Accordingly, the present invention is directed to a vaccine, which corresponds to a pharmaceutical composition of the invention (second embodiment),... |
| Process for identification of molecular mimicry and the uses thereof | 20090324582 | 20091231 |
| The present invention discloses a process for simple and rapid detection and identification of molecular mimicry or mimic antigens or molecules existing in/on humans, animals and plants. The molecular mimicry can be related to infections, autoimmune diseases, cancers, obesity and other disorders. Therefore, novel methods for the diagnosis, prevention, and treatment of infections, autoimmune diseases, cancers, obesity and other disorders obtainable based on these mimic antigens or molecules can be developed. Furthermore, the present invention also reveals a new functional mechanism of vaccine and passive immunity and novel vaccines obtainable based on the new mechanism.
... |
| Mutated immunogenic peptides derived from r9m, polynucleotides coding for same and therapeutic uses thereof | 20090324556 | 20091231 |
| The invention concerns the optimization of the wild R9M peptide and the use of the resulting peptides for therapeutic vaccination and/or preventive vaccination against leukaemia in humans. More particularly, the invention concerns mutated immunogenic peptides derived from the human TEL/AML1 fusion protein comprising the wild R9M peptide sequence Arg-Ile-Ala-Glu-Czs-Ile-Leu-Gly-Met. The invention also concerns polynucleotides coding for the mutated R9M immunogenic peptides, cellular expression vectors comprising nucleic acid sequences expressing the mutated R9M immunogenic peptides and polyclonal or monoclonal antibodies capable of being fixed on at least one of said peptides/polynucleotides. The invention further concerns the use of said peptides, polynucleotides and/or antibodies for preparing vaccines, anti-tumoral medicines and compositions and for in vitro and in vivo stimulation of the immune response in humans.
... |
| Vaccinia virus strains | 20090324548 | 20091231 |
| The invention provides attenuated vaccinia virus vaccines that can be used in methods to prevent or treat small pox in patients, as well as methods of obtaining such vaccines.
... |
| Vaccine carrier | 20090324501 | 20091231 |
| The present invention relates to a hypoallergenic protein consisting of at least one hypoallergenic molecule derived from an allergen, which is fused or conjugated to at least one second non-allergenic protein or fragment thereof.
... |
| Method for assaying antigens | 20090317919 | 20091224 |
| A method for assaying an antigen adsorbed on a solid support is provided. The method comprises: a) contacting a suspension of the antigen adsorbed on the solid support with a solution or suspension of an optionally detectably-labelled primary antibody to the antigen to form a solid-supported antigen-antibody complex; b) where the primary antibody is detectably labelled, optionally measuring the detectable label thereby to determine the quantity of the antigen; or c) contacting the solid-supported antigen-antibody complex with a detectably-labelled probe for the solid-supported antigen-antibody complex; and d) measuring the detectable label on the probe, thereby to determine the quantity of antigen. The antigen is preferably a component of a sub-unit vaccine, and most preferably anthrax protective antigen.
... |
| Immunogenic t-helper epitopes from human tumour antigens and immunotherapeutic methods using said epitopes | 20090317428 | 20091224 |
| The present invention relates to immunotherapeutic methods, and molecules and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer, in particular renal cancer. The present invention furthermore relates to tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides, that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumour immune responses. In particular, the present invention relates to 338 novel peptide sequences derived from HLA class II molecules of human tumour cell lines which can be used in vaccine compositions for eliciting anti-tumour immune responses.
... |
| Refrigerator-temperature stable influenza vaccine compositions | 20090317425 | 20091224 |
| Methods and compositions for the optimization and production of refrigerator-temperature stable virus, e.g., influenza, compositions are provided. Formulations and immunogenic compositions comprising refrigerator-temperature stable virus compositions are provided.
... |
| Pcv2 mycoplasma hyopneumoniae immunogenic compositions and methods of producing such compositions | 20090317423 | 20091224 |
| Multivalent combination vaccines are provided which include an immunological agent effective for reducing the incidence of or lessening the severity of M. hyo infection, preferably M. hyo bacterin, or an immunogenic composition comprising M. hyo bacterin, and at least one immunogenic active component of another disease-causing organism in swine, preferably PCV2 wherein the preferred PCV2 antigen for such a multivalent vaccine is PCV2 ORF 2 protein.
... |
| Oral vaccines | 20090317424 | 20091224 |
| This invention features a composition that includes a multiple-cell organism for use as food for an aquatic animal (e.g., a fish or a shrimp), and a single-cell organism fed to, and as a result, bioencapsulated by, the multiple-cell organism. The single-cell organism has been transformed to express a recombinant antigen that induces an immune response in the aquatic animal.
... |
| Use of ppd for the adjuvantation of a nucleic acid vaccine | 20090317422 | 20091224 |
| The present invention provides a novel adjuvant for nucleic acid vaccines, and in particular the present invention provides nucleic acid vaccines that comprise, or are administered in association with PPD. The present invention also provides methods to improve the therapeutic efficacy of nucleic acid vaccines.
... |
| Tetramers | 20090317419 | 20091224 |
| The present invention relates, in general to human immunodeficiency virus (HIV), and, in particular, to B cell tetramers and to methods of using same for diagnosis, disease monitoring and vaccine development.
... |
| Vaccines and methods for prevention and treatment of drug-resistant hiv-1 and hepatitis b virus | 20090317418 | 20091224 |
| The present invention provides methods for lowering a viral load of a virus resistant to an antiviral drug by inducing cytotoxic T lymphocytes (CTL) to recognize a predetermined mutated epitope within a viral protein of the drug-resistant virus. CTLs are induced by immunizing a host with a peptide comprising the predetermined mutation. The immunostimulating peptide may be further improved by epitope-enhancement for inducing specific CTLs. The antiviral protection against drug-resistant virus shown by compositions of the present invention and mediated by human HLA-restricted CTL has not been previously achieved.
... |
| Vaccine composition comprising alpha-galactosylceramide as an adjuvant for intranasal administration | 20080317769 | 20081225 |
| The present invention related to a vaccine composition comprising alpha-galactosylceramide (αGalCer) as an adjuvant for the intranasal administration. The present inventors administered αGalCer together with a tumor cell antigen or a virus antigen to the nasal cavity of a mouse and then confirmed that the αGalCer effectively induced not only humoral immunity but also cell-mediated immunity. Thus, the αGalCer can be effectively used as an adjuvant for a vaccine by the intranasal administration for the prevention and treatment of virus infection and cancer.
... |
| Compounds and methods for treatment and diagnosis of chlamydial infection | 20080317772 | 20081225 |
| Compounds and methods for the diagnosis and treatment of Chlamydial infection are disclosed. The compounds provided include polypeptides that contain at least one antigenic portion of a Chlamydia antigen and DNA sequences encoding such polypeptides. Pharmaceutical compositions and vaccines comprising such polypeptides or DNA sequences are also provided, together with antibodies directed against such polypeptides. Diagnostic kits containing such polypeptides or DNA sequences and a suitable detection reagent may be used for the detection of Chlamydial infection in patients and in biological samples.
... |
| Bacterial antigens and uses thereof | 20080317775 | 20081225 |
| Novel enzymes, processes and antigenic structures useful in producing vaccines and compounds useful in combating gram-negative bacteria are described. Enzymes were isolated from the slime mould Dictyostelium discoideum and used to specifically degrade lipopolysaccharide (LPS). Enzymatic degradation permits residues of the LPS molecule, including immunogenic epitopes of the core oligosaccharide portion of the LPS, to remain unmodified during this enzymatic removal of fatty acids from the lipid A region of the LPS molecule.
... |
| Vaccines containing viruses involved in avian malabsorption syndrome and methods of administration therefor | 20080317776 | 20081225 |
| The causative agent(s) of Avian Malabsorption Syndrome (MAS) are isolated and used to prepare vaccines for use in the prevention of diseases resultant therefrom. The vaccines contain at least two avian viruses—the reovirus and adenovirus—and optionally include another virus which inflicts poultry. The viruses may be live, attenuated live, or inactivated when incorporated into the vaccine. The vaccine itself may be administered in ovo, to new-born or growing chicks, or to adult fowl.
... |
| Cdna construct of salmonidae alphavirus | 20080317777 | 20081225 |
| The invention concerns recombinant DNA's comprising cDNA of genomic RNA of a Salmonidae alphavirus preceded by a spacer sequence, under the control of a suitable promoter. Said recombinant DNA's are useful for obtaining expression vectors, producing recombinant Salmonidae alphavirus, and for obtaining vaccines.
... |
| Modified vaccinia ankara virus variant and cultivation method | 20080317778 | 20081225 |
| The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus and characterized by the loss of its capability to reproductively replicate in human cell lines. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus. In addition, a method is provided for the administration of a therapeutically effective amount of the virus, or its recombinants, in a vaccinia virus prime/vaccinia virus boost inoculation regimen. The present invention relates to a method of virus amplification in primary cells which are cultivated in... |
| Viral vaccine and method for preparation thereof | 20080317780 | 20081225 |
| The invention relates to a viral vaccine, especially a retroviral vaccine, and methods of forming such a vaccine. The vaccine is formed from a whole-killed virus suspension in a cell lysate or culture medium, wherein the virus is killed by exposure to a chloramine compound at a level adequate to inactivate zinc finger proteins. The chloramine compound may be taurine chloramine, adenosine chloramine, phenylalanine chloramine, and alanine chloramine. The vaccine may be used as a prophylactic or therapeutic vaccine and may be developed from a subject's own strains of virus so as to be considered an autologous vaccine.
... |
| Vaccines for diseases of fish | 20080317781 | 20081225 |
| Fish are immunized by a mass vaccination method, such as by immersion in water containing an attenuated strain of a pathogenic bacterium that does not effectively cause disease in fish when the non-attenuated pathogenic bacterium is exposed to the fish by immersion. An illustrative example of the method is for immunizing against coldwater disease caused by Flavobacterium psychrophilum, which may be attenuated by serial passage in media containing increasing amounts of an antibiotic, such as rifampicin.
... |
| Vaccine | 20080317785 | 20081225 |
| The invention provides a vaccine comprising secreted protein derived from Mycobacterium avium subsp paratuberculosis (M. ptb) substantially free of whole organisms of that species either dead or alive. The secreted protein may be obtained from a culture of M. ptb with the microorganisms being removed by centrifugation and subsequent filtration. The vaccine may be used for vaccination against Johne's disease
... |
| Genetically modified babesia parasites expressing protective tick antigens and uses thereof | 20080317786 | 20081225 |
| The present invention relates to methods for stable transfection of Babesia parasites, and for vaccines conferring immunity against parasitic arthropods.
... |
| Anti-malaria vaccine | 20080317787 | 20081225 |
| There is provided, inter alia, a method for the prophylaxis of productive malaria infection in travelers to endemic regions comprising the administration of suitable amounts of a formulation comprising a Plasmodium antigen or an immunogenic fragment or derivative thereof and an adjuvant, comprising a lipid A derivative and a saponin in a liposome formulation.
... |
| Liposomal vaccine compositions comprising a polysaccharide antigen and a protein adjuvant | 20080317838 | 20081225 |
| A liposomal composition, preferably a vaccine, comprising liposomes formed of liposome forming compounds, containing coentrapped polysaccharide antigen and T-cell dependent protein carrier, such as tetanus toxoid or diphtheria toxin modified to render it non-toxic. The invention is of use in the production of vaccines against Haemophilus influenzae, Streptococcus pneumoniae or Neisseria meningitidis.
... |
| Methods and compositions for combinatorial-based production of multivalent recombinant antigens | 20080318274 | 20081225 |
| The present invention provides methods and compositions for rapidly producing multivalent recombinant vaccines using filamentous fungal heterokaryons. The present invention relies on the use of filamentous fungal heterokaryons that are generated from combinations of two or more parent strains into which recombinant DNA molecules encoding variants of antigens derived from pathogenic organisms have been introduced. The resulting vaccines are multivalent.
... |
| Method of producing meningococcal meningitis vaccine for neisseria meningitidis serotypes a, c, y, and w-135 | 20080318285 | 20081225 |
| Methods for producing quadrivalent meningococcal meningitis polysaccharide and conjugate vaccines for sero types A, C, Y and W-135 disclosed. Neisseria meningitidis fastidious medium was designed to maximize the yield of capsular polysaccharides and generate minimal cellular bio mass and endotoxin in a short duration of fermentation. The crude polysaccharides are isolated, purified and mechanically depolymerized by sonication. These purified polysaccharides were found in human clinical trials to be safe and immunogenic against meningococcal disease caused by N. meningitidis A, C, Y and W-135 sero groups in sub-Saharan Africa. In the preferred embodiment, the polysaccharides are conjugated to carrier proteins of diphtheria or tetanus toxoid to an average molecular size of 5100 to 9900 Daltons and provide broad spectrum protection to humans of all ages. Accelerated polysaccharide... |
| Methods of monitoring acceptance criteria of vaccine manufacturing systems | 20080319694 | 20081225 |
| Methods of monitoring an acceptance criteria of vaccine manufacturing processes are disclosed herein. Consequently, the methods and systems provide a means to perform high-quality manufacturing on an integrated level whereby vaccine manufacturers can achieve data and product integrity and ultimately minimize cost.
... |
| Product comprising a c4bp core protein and a monomeric antigen, and its use | 20080311106 | 20081218 |
| The invention provides a product which comprises a C4bp core protein and a monomeric antigen, desirably in the form of a fusion protein. Monomeric antigens include malarial and influenza antigens. The C4bp core protein provides for assembly of multimeric complexes of the monomeric antigen, or mixtures thereof. The complexes are useful as vaccines.
... |
| Polypeptides | 20080311108 | 20081218 |
| The invention relates to antigenic polypeptides expressed by pathogenic microbes, vaccines comprising said polypeptides; therapeutic antibodies directed to said polypeptides and methods to manufacture said polypeptides, vaccines and antibodies.
... |
| Chimeric vaccine for haemophilus influenzae-induced disease | 20080311110 | 20081218 |
| The invention described herein relates to a chimeric protein comprising the NTHi twitching pilus major subunit protein (PilA) presenting a portion of the NTHi OMP P5 protein. The invention provides for vaccine compositions comprising the recombinant chimeric protein and methods of eliciting an immune response using the recombinant chimeric proteins of the invention.
... |
| Antisense oligonucleotides directed to ribonucleotide reducatase r2 and uses thereof in combination therapies for the treatment of cancer | 20080311126 | 20081218 |
| Combination products comprising an antisense oligonucleotide against the gene encoding a mammalian ribonucleotide reductase R2 protein and one or more immunotherapeutic agents, such as cytokines, non-cytokine adjuvants, monoclonal antibodies and cancer vaccines. The combinations can further comprise one or more chemotherapeutic agents. Methods of treating cancer in a mammal using the combinations are also provided.
... |
| Carcinoembryonic antigen fusions and uses thereof | 20080311137 | 20081218 |
| Polynucleotides encoding carcinoembryonic antigen (CEA) fusion proteins are provided, the CEA fusion proteins comprising a CEA protein, or functional variant thereof, fused to a substantial portion of an immunoenhancing element. The polynucleotides of the present invention can elicit an immune response in a mammal, which, in preferred embodiments, is stronger than the immune response elicited by a wild-type CEA. The gene encoding CEA is commonly associated with the development of human carcinomas. The present invention provides compositions and methods to elicit or enhance immunity to the protein product expressed by the CEA tumor-associated antigen, wherein aberrant CEA expression is associated with a carcinoma or its development. This invention specifically provides adenoviral vector and plasmid constructs carrying polynucleotides encoding CEA fusion proteins and discloses their use in... |
| Adjuvant activity of gastrointestinal peptides | 20080311138 | 20081218 |
| Gastrointestinal peptides (GPs) have been found to function as vaccine adjuvants, and in particular as mucosal adjuvants. The invention provides an immunogenic composition comprising: (a) a GP adjuvant; and (b) an antigen. The composition is preferably suitable for mucosal administration e.g. intranasal administration.
... |
| Plant produced vaccine for amebiasis | 20080311139 | 20081218 |
| Disclosed herein are methods of making a vaccine against Entamoeba histolytica and methods of immunizing a subject using such vaccine. Specifically exemplified are plants expressing a LecA polypeptide and plant material obtained from such plant being used as a basis for vaccination.
... |
| Cancer vaccines and vaccination methods | 20080311141 | 20081218 |
| Methods and compositions for treating cancers (e.g., neural cancers) by dendritic cell vaccination are provided herein.
... |
| Cancer vaccines and vaccination methods | 20080311142 | 20081218 |
| Methods and compositions for treating cancers (e.g., neural cancers) by dendritic cell vaccination are provided herein.
... |
| Construction of chimera prrsv, compositions and vaccine preparations | 20080311143 | 20081218 |
| Chimeric replicons of North American Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) containing the 5′ sequence of an avirulent strain of PRRSV and a 3′ sequence of a virulent strain of PRRSV are provided. Further provided is a method of producing attenuated PRRSV from the chimeric replicon. Also provided are compositions containing the replicon or attenuated virus. Vaccines and a method of vaccinating pigs against PRRSV are also provided.
... |
| Protein cage immunotherapeutics | 20080311145 | 20081218 |
| The present invention provides compositions of heat shock protein cages for use in therapeutic vaccines. The heat shock protein cages of the invention have attached antigen, located either on the interior or exterior of the protein cage, and optionally an adjuvant.
... |
| Rhabdoviral n-fusion proteins as carrier for foreign antigens | 20080311147 | 20081218 |
| Rabies virus (RV) nucleoprotein (N) tightly encapsidates the genomic and antigenomic RNA thereby forming the ribonucleoprotein (RNP) complex. Antigens presented in a rigid and repetitive organization are sufficient to activate B cells to proliferate. In addition to the repetitive organization, it has been shown that RV N protein induces potent T-helper responses resulting in long-lasting and strong humoral immune responses against RV. The possibility to directly manipulate the genome of RV allows us to examine whether the immunogenicity of foreign antigens can be enhanced via incorporation into the RNP structure. A recombinant RV expressing an RV N-green fluorescent protein (GFP) fusion protein. The chimeric N-GFP fusion protein was efficiently expressed and incorporated into RV RNP and virions. Moreover, the recombinant RNP induces a strong humoral immune... |
| Dna-transfection system for the generation of infectious influenza virus | 20080311148 | 20081218 |
| The present invention is based on the development of a dual promoter system (preferably a RNA pol I-pol II system) for the efficient intracellular synthesis of viral RNA. The resultant minimal plasmid-based system may be used to synthesize any RNA virus, preferably viruses with a negative single stranded RNA genome. The viral product of the system is produced when the plasmids of the system are introduced into a suitable host cell. One application of the system is production of attenuated, reassortant influenza viruses for use as antigens in vaccines. The reassortant viruses generated by cotransfection of plasmids may comprise genes encoding the surface glycoproteins hemagglutinin and neuraminidase from an influenza virus currently infecting the population and the internal genes from an attenuated influenza virus. An advantageous... |
| Dna-transfection system for the generation of infectious influenza virus | 20080311149 | 20081218 |
| The present invention is based on the development of a dual promoter system (preferably a RNA pol I-pol II system) for the efficient intracellular synthesis of viral RNA. The resultant minimal plasmid-based system may be used to synthesize any RNA virus, preferably viruses with a negative single stranded RNA genome. The viral product of the system is produced when the plasmids of the system are introduced into a suitable host cell. One application of the system is production of attenuated, reassortant influenza viruses for use as antigens in vaccines. The reassortant viruses generated by cotransfection of plasmids may comprise genes encoding the surface glycoproteins hemagglutinin and neuraminidase from an influenza virus currently infecting the population and the internal genes from an attenuated influenza virus. An advantageous... |
| Vaccine for periodontal disease | 20080311151 | 20081218 |
| The present invention relates to novel bacterial isolates identified by their 16S rRNA DNA, that cause periodontal disease in companion animals, polynucleotide sequences contained therein, polypeptides encoded by such polynucleotide sequences and vaccines comprising such bacteria, polynucleotides, or polypeptides. Also provided are methods for treating and preventing periodontal disease and kits for detecting and treating periodontal disease kits for detecting and preventing periodontal disease. In addition, methods for assessing the efficacy of a vaccine against periodontal diseases in an animal are provided.
... |
| Method and vaccine for non-genetically engineered atavism growth enhancement | 20070298045 | 20071227 |
| A method and vaccine for non-genetically engineered atavism growth enhancement, which injects the vaccine with myostatin antibody containing muscular tissues into the vertebrate mother's body prior to the pregnancy stage; the genes of myostatin that contain muscular tissues can enhance the muscular mass and growth rate of the muscle.
... |
| Identification of gene sequences and proteins involved in vaccinia virus dominant t cell epitopes | 20070298046 | 20071227 |
| The present invention relates to the identification of gene sequences and proteins involved in vaccinia virus dominant T cell epitopes. Two vaccinia virus CD8+ T cell epitopes restricted by the most common human MHC class I allele, HLA-A0201 have been identified. Both epitopes are highly conserved in vaccinia and variola viruses. The induction of the T cell responses following primary vaccination is demonstrated by the kinetics of epitope specific CD8+ T cells in 3 HLA-A0201 individuals. This information will be useful for the design and analyses of the immunogenicity of experimental vaccinia vaccines, and for basic studies of human T cell memory.
... |
| Adjuvants of immune response | 20070298051 | 20071227 |
| The present invention features methods to substantially increase the immunogenicity of a vaccine, preferably a DNA vaccine, and involves providing a mammal with a vaccine regimen, which includes an immunogen and Flt3L in combination with MIP-1α or MIP-3α. The methods of the present invention can be used for the prevention and treatment of various pathological states, including for example, cancer, microbial infections, autoimmune diseases, tissue rejection, and allergic reactions.
... |
| Cattle reproductive disease vaccines | 20070298053 | 20071227 |
| The present invention relates to combination vaccines and methods for treating or preventing diseases or disorders in an animal caused by infection by Bovine Viral Diarrhea Virus (BVDV) Types 1 and 2, Bovine Herpes Virus Type-1 (BHV-1), Bovine Respiratory Syncytial Virus (BRSV), Parainfluenza Virus (PI3), Campylobacter fetus, Leptospira canicola, Leptospira grippotyphosa, Leptospira hardj-prajitno, Leptospira icterohaemmorrhagiae, Leptospira hardjo-bovis and Leptospira pomona by administering to the animal an effective amount of a combination vaccine. The combination vaccine can be a whole or partial cell inactivated or modified live preparation.
... |
| Highly safe smallpox vaccine virus and vaccinia virus vector | 20070298054 | 20071227 |
| Objects of the present invention are to generate vaccine strains that undergo reversion (atavism) with difficulty and to provide smallpox vaccines with higher safety. The vaccine viruses are deficient in a part or the whole of the B5R gene of a vaccinia viral strain, LC16m8 or LC16mO, and produce no B5R gene products having normal functions. The vaccine viruses can be used as smallpox vaccines or vectors capable of expressing foreign genes. Hence, smallpox vaccines and vaccinia virus vectors are provided that produce no B5R gene products having normal functions due to reverse mutation.
... |
| Assay to detect hcv receptor binding | 20070298410 | 20071227 |
| Identification of HCV receptor target cells using HCV receptor-binding ligands and cell separation by flow cytofluorimetry is described. HCV receptor target cells are employed to conduct assays for HCV receptor-binding ligands in order to identify potential HCV vaccine candidates. HCV receptor target cells are used to measure antibody neutralisation to monitor vaccine development, as a diagnostic of HCV infection and to develop neutralising antibodies for passive immunisation.
... |
| Vaccine formulations for intradermal delivery comprising adjuvants and antigenic agents | 20070292386 | 20071220 |
| The present invention relates to compositions for intradermal delivery of an antigenic or immunogenic agent in combination with one or more adjuvants. The immunogenic compositions of the invention comprise an antigenic or immunogenic agent and at least one adjuvant, which enhances the immune response to the antigenic or immunogenic agent, once delivered to the intradermal compartment of a subject's skin. The immunogenic compositions of the invention have enhanced efficacy as the adjuvants of the composition promote recruitment of antigen presenting cells to the intradermal compartment and thus enhance presentation and/or availability of the antigenic or immunogenic agent to the antigen presenting cells. The enhanced efficacy of the immunogenic compositions of the invention results in a therapeutically and/or prophylactically effective immune response after a single intradermal dose,... |
| Broadly cross-reactive hiv-1 neutralizing human monoclonal antibodies | 20070292390 | 20071220 |
| The invention provides polypeptides that bind with an epitope of the gp41 subunit of the HIV-1 envelope glycoprotein, as well as polypeptides comprising the aforementioned epitopes. The invention also provides methods of inhibiting an HIV infection in a mammal using the polypeptides of the invention, as well as compositions comprising the polypeptides, nucleic acid molecules encoding the polypeptides, and host cells and vectors comprising the nucleic acid molecules. A method of isolating antibodies that bind with an epitope of the gp41 subunit of the HIV-1 envelope glycoprotein using competitive antigen panning (CAP) is also provided. The invention also features the use of the polypeptides to detect the presence of HIV in a mammal, and epitopes that can be used as vaccine immunogens.
... |
| Chlamydia pmp proteins, gene sequences and uses thereof | 20070292425 | 20071220 |
| The invention discloses the Chlamydia PMPE and PMPI polypeptide, polypeptides derived therefrom, (PMP-derived polypeptides), nucleotide sequences encoding said polypeptides, antibodies that specifically bind the PMP polypeptides and PMP-derived polypeptides and T-cells specific for PMP polypeptides and PMP-derived polypeptides. Also disclosed are prophylactic and therapeutic compositions, including immunogenic compositions, e.g., vaccines, comprising PMP polypeptides or PMP-derived polypeptides or antibodies thereto. The invention additionally discloses methods of inducing in animals an immune response to Chlamydia cells, Chlamydia elementary bodies, and/or cells expressing Chlamydial proteins, e.g., cell infected with Chlamydia.
... |
| Chlamydia pmp proteins, gene sequences and uses thereof | 20070292437 | 20071220 |
| The invention discloses the Chlamydia PMPE and PMPI polypeptide, polypeptides derived therefor, (PMP-derived polypeptides), nucleotide sequences encoding said polypeptides, antibodies that specifically bind the PMP polypeptides and PMP-derived polypeptides and T-cells specific for PMP polypeptides and PMP-derived polypeptides. Also disclosed are prophylactic and therapeutic compositions, including immunogenic compositions, e.g., vaccines, comprising PMP polypeptides or PMP-derived polypeptides or antibodies thereto. The invention additionally discloses methods of inducing in animals an immune response to Chlamydia cells, Chlamydia elementary bodies, and/or cells expressing Chlamydial proteins, e.g., cell infected with Chlamydia.
... |
| Peptide minotopes of mycobacterial mannosylated lipoglycans and uses thereof | 20070292447 | 20071220 |
| The present invention relates to the identification of antigenic and immunogenic peptide-based mimicry of mannose-containing cell-wall compounds characterizing mycobacterial infectious agents, such as Mycobacterium tuberculosis. Amino acid molecules which are mimotopes of mannosylated lipoglycans, such as lipoarabinomannan (ManLAM), including at least one of the following characteristics: (a) being capable of binding to ManLAM binding antibodies; (b) being capable of eliciting production of ManLAM binding antibodies, are provided. Also diagnostic methods for diagnosing mycobacterial infections and methods of vaccinating subjects against such infections. The diagnostic and vaccination methods employ the provided amino acid molecules. Accordingly, a diagnostic kit and a vaccine for executing the aforementioned methods are provided.
... |
| Preloaded dendritic cell vaccines for treating cancer | 20070292448 | 20071220 |
| This disclosure provides a technology for making a dendritic cell vaccine suitable for high volume manufacturing and distribution. Human stem cells are differentiated in a multi-step protocol to generate cell populations bearing a dendritic cell phenotype. The cells are loaded by pulsing with a specific tumor antigen, or by activation of an inducible transgene. The primed dendritic cells are powerful components of a vaccination strategy to elicit an immune response against tumor-associated antigens like telomerase. Vaccines and reagent combinations prepared according to this invention can be used on demand as off-the-shelf products for treating cancer.
... |
| Vaccine compositions which are obtained from streptomyces | 20070292452 | 20071220 |
| The present invention relates to the field of immunology, specifically to the control of infectious diseases caused by mycobacteria using vaccines developed from live strains of Streptomyces, expressing or not antigens of M. tuberculosis, which demonstrated their protective capacity against challenge with BCG and M. tuberculosis after being administered by different routes.
... |
| Rna virus vaccines and methods | 20070292453 | 20071220 |
| The invention is a vaccine, and method of vaccination, against RNA viruses, including RNA viruses in the family Flaviviridae, which includes for example West Nile Virus, Yellow fever virus, Dengue fever virus, Hepatitis C virus, Pestiviruses, Bovine viral diarrhea virus, and Classical Swine fever virus, wherein the vaccine comprises the RNA virus or immunogenic portions thereof, which have been treated with and rendered non-pathogenic by a phenothiazine dye and visible light, the phenothiazine dyes, including, but not limited to, Methylene Blue (MB), Methylene Green, 1-methyl MB, 1,9-dimethyl MB, Azure A, Azure B, Azure C, thionine, and toluidine blue, or by squalene. The invention includes novel strains of WNV for use in producing a vaccine, and novel primers and their use in recognizing and amplifying all of... |
| Therapeutic calcium phosphate particles and methods of manufacture and use | 20070292454 | 20071220 |
| Novel calcium phosphate core particles, methods of making them, and methods of using them as vaccine adjuvants, as cores, as carriers of biologically active material, and as controlled release matrices for biologically active material are disclosed. The core particles may have a surface modifying agent and/or biologically active material, such as antigenic material or natural immunoenhancing factor, polynucleotide material, or therapeutic proteins or peptides, partially coating the particle or impregnated therein. The core particles have a diameter between about 300 nm and about 4000 nm, more particularly between about 300 nm and about 2000 nm, and even more particularly between about 300 nm and about 1000 nm, are substantially spherical in shape, and have a substantially smooth surface
... |
| Synthetic gagpol genes and their uses | 20070293448 | 20071220 |
| The present invention relates to synthetic gag and gagpol genes optimized for high level expression via codon optimization and the uses thereof for the efficient generation of vector particles. The invention further relates to the generation of packaging cells and vaccines based on the synthetic gag and gagpol genes.
... |
| Injection device for administering a vaccine | 20070293826 | 20071220 |
| A manually-powered injection device that self-administers a painless injection. The injection device provides a method for substantially painless injections of vaccine and other medication into a patient that does not require the use of an anesthetic, that does not require the medical personnel to spend a substantial amount of time performing the injection procedure, that is relatively simple and inexpensive to perform and operate, and that provides a relatively high degree of safety for both the medical personnel and for the patient. The injection needle can have an outside diameter greater than 0.10 mm and less than about 0.38 mm. The vaccine or other medicament can be injected painlessly through the needle and into the patient at a substantially constant volumetric flow rate of about 0.05... |
| Recombinant polypeptides of the members of the tnf ligand family and use thereof | 20070286843 | 20071213 |
| The invention relates to polypeptides comprising, as constituent A, at least three monomers of a member of the TNF ligand family and, as constituent B, at least two peptide linkers that link the monomers of the member of the TNF ligand family to one another. The invention also relates to the use of these polypeptides for treating diseases and for producing a medicament or a vaccine. The invention also relates to methods for producing and isolating these polypeptides, to nucleic acids that code for these polypeptides, to vectors containing these nucleic acids, to host cells transfected with these vectors, and to pharmaceutical compositions containing these inventive objects. Finally, the invention relates to methods for the extracorporeal manipulation, depletion and/or removal of components contained in body fluids,... |
| Adoptive immune cells for tumor vaccines | 20070286847 | 20071213 |
| The present invention provides a method for preparing adoptive immune cells comprising the following steps of a) obtaining mammalian antigen-presenting associated cells; b) culturing the resulting cells in a culture vessel coated with a sugar chain-containing polymer; and c) detaching the cells by shaking the culture vessel without treating the cells with enzyme and without using a cell detaching tool; adoptive immune cells obtained by this preparing method; a culture vessel coated with a sugar chain-containing polymer for use in this preparation method; a kit for preparing an adoptive immune cell vaccine; and a method and a medicine for treating a malignant tumor, type I diabetes, atopic allergic diseases or infections using the adoptive immune cells.
... |
| Influenza virus vaccine composition and methods of use | 20070286869 | 20071213 |
| The present invention is directed to enhancing the immune response of a human in need of protection against IV infection by administering in vivo, into a tissue of the human, at least one polynucleotide comprising one or more regions of nucleic acid encoding an IV protein or a fragment, a variant, or a derivative thereof. The present invention is further directed to enhancing the immune response of a human in need of protection against IV infection by administering, in vivo, into a tissue of the human, at least one IV protein or a fragment, a variant, or derivative thereof. The IV protein can be, for example, in purified form or can be an inactivated IV, such as those present in inactivated IV vaccines. The polynucleotide is... |
| Vaccines | 20070286871 | 20071213 |
| The present invention relates to compositions for inducing immune responses, including an antigen and a promiscuous T-cell epitope. Also provided are methods of inducing immune responses in hosts, comprising administering compositions comprising antigens and promiscuous T-cell epitopes to the host.
... |
| Live attenuated nidovirus vaccines | 20070286872 | 20071213 |
| The present invention is directed live, attenuated Nidovirus vaccines, and in a particular embodiment, to coronavirus vaccines. The vaccine comprises a viral genome encoding a replicase polyprotein having at least one proteinase cleavage site that exhibits reduced or no cleavage. Such viruses show reduced.
... |
| Recombinant influenza h5 hemagluttinin protein and nucleic acid coding therefor | 20070286873 | 20071213 |
| The present invention provides an improved form of a nucleic acid encoding for the influenza hemagluttinin H5N1. The optimized gene sequence permits production via recombinant means, of the H5N1 HA protein for use in diagnostic assays and vaccines.
... |
| Recombinant attenuated clostridium organisms and vaccine | 20070286874 | 20071213 |
| The present invention discloses attenuated Clostridium perfringens organisms that express a substantially nontoxic alpha-toxin. The expressed alpha-toxin is a deletion mutein that relative to the alpha-toxin of the mature alpha-toxin of Clostridium perfringens strain 13, is missing at least nine consecutive amino acid residues including His68. The present invention also discloses attenuated organisms that encode the muteins, as well as the use of such attenuated organisms as vaccines.
... |
| Adjuvant in the form of a lipid-modified nucleic acid | 20070280929 | 20071206 |
| The present invention relates to an immune-stimulating adjuvant in the form of a lipid-modified nucleic acid, optionally in combination with further adjuvants. The invention relates further to a pharmaceutical composition and to a vaccine, each containing an immune-stimulating adjuvant according to the invention, at least one active ingredient and optionally a pharmaceutically acceptable carrier and/or further auxiliary substances and additives and/or further adjuvants. The present invention relates likewise to the use of the pharmaceutical composition according to the invention and of the vaccine according to the invention for the treatment of infectious diseases or cancer diseases. Likewise, the present invention includes the use of the immune-stimulating adjuvant according to the invention in the preparation of a pharmaceutical composition for the treatment of cancer diseases or infectious... |
| Prostatic acid phosphatase antigens | 20070280939 | 20071206 |
| The invention relates to peptides from Prostatic Acid Phosphatase (PAP), especially those identified as PAP.135 and PAP.161. The nucleic acid molecules encoding the peptides, antibodies against the peptides, and the use of such peptides, nucleic acids and antibodies in immunotherapy, vaccines and assays are also included in the scope of the invention.
... |
| Amyloid beta gene vaccines | 20070280953 | 20071206 |
| The invention generally concerns compositions and methods for genetic vaccination with amyloid beta (Aβ) protein. Such vaccines may provide effective treatment for neurodegenerative disease such as Alzheimer's disease. Vaccination methods are can be used to induce a Th2 type immune response directed to Aβ. This immune response id shown to substantially reduce Aβ concentration and Aβ plaque size in an Alzheimer's model system.
... |
| Novel virulence determinant within the e2 structural glycoprotein of classical swine fever virus | 20070280955 | 20071206 |
| Classical Swine Fever Virus (CSFV) E2 glycoprotein is a major inducer of neutralizing antibodies and protective immunity in swine. E2 mediates virus adsorption to the target cell, and harbors genetic determinants associated with virus virulence. CSFV E2 also contains between residues 829 and 837 a discrete epitope (TAVSPTTLR) recognized by monoclonal antibody (mAb) WH303, used to differentiate CSFV from related Pestiviruses Bovine Viral Diarrhea Virus (BVDV) and Border Disease Virus (BDV). In this report, a CSFV infectious clone of the virulent Brescia isolate (BICv) was used to progressively mutate the mAb WH303 epitope of CSFV E2 to the homologous amino acid sequence of BVDV strain NADL E2 (TSFNMDTLA). While the resulting virus mutants T1v (TSFSPTTLR), T2v (TSFNPTTLR), T3v (TSFNMTTLR) demonstrated in vitro growth characteristics similar to... |
| Novel hepatitis c virus peptides and uses thereof | 20070280956 | 20071206 |
| Novel hepatitis C virus (HCV) polypeptides are provided which are not encoded by the standard HCV open reading frame. These alternate reading frame polypeptides are useful, inter alia, in vaccine compositions, in diagnosing HCV infection, and as therapeutic targets.
... |
| Change of the load state of mhc molecules | 20070280957 | 20071206 |
| The present invention relates to methods for changing the load state of MHC molecules with ligands, the change in the load state being catalysed by a compound of formulae I, IA, II, III or IV1 to IV3. The invention relates further to the use of compounds of formulae I, IA, II, III or IV1 to IV3 or to the use of MHC molecules loaded with ligands, which molecules can be prepared by a method according to the invention, for the treatment of disorders or conditions that are associated with various pathologically excessive or absent immune responses and also for triggering tumour-specific, pathogen-specific or autoreactive immune responses. The invention additionally relates to the use of such compounds for the treatment and diagnosis of cancer, infectious diseases, autoimmune... |
| Modulation of negative immune regulators and applications for immunotherapy | 20060292119 | 20061228 |
| The invention includes compositions and methods for enhancing immunopotency of an immune cell by way of inhibiting a negative immune regulator in the cell. The present invention provides vaccines and therapies in which antigen presentation is enhanced through inhibition of negative immune regulators. The present invention also provides a mechanism to break self tolerance in tumor vaccination methods that rely on presentation of self tumor antigens.
... |
| Tumour cell lines nm-f9 (dsm acc2606) and nm-d4 (dsm acc2605), uses thereof | 20060292129 | 20061228 |
| The present invention relates to a cell line selected from the group consisting of (a) a cell line denominated NM-F9 having the DSMZ accession number DSM ACC2606; (b) a cell line denominated NM-D4 having the DSMZ accession number DSM ACC2605; and subclones of (a) or (b). Additionally, the present invention provides a lysate of the cell lines or a molecule or mixture of molecules obtained from these cell lines as well as dendritic cells loaded with said lysate, co-cultivated or fused with cells from the cell lines, or a molecule or mixture of molecules obtained from these cell lines of the present invention. Moreover compositions, preferably pharmaceutical or vaccine compositions are provided which comprise the cell lines, lysate, molecules, mixture of molecules or dendritic cells of... |
| Allergen vaccine proteins for the treatment and prevention of allergic diseases | 20060292138 | 20061228 |
| The present invention provides fusion proteins comprising an allergen sequence linked via an IgG hinge region to another polypeptide sequence capable of specifically binding to a native IgG inhibitory receptor containing an immune receptor tyrosine based inhibitory motif (ITIM). They are designed to cross-link an Fc receptor for IgE (e.g., FcεR1) and an IgG inhibitory receptor (e.g., FcγRIIb), thereby inhibiting the IgE-driven mediators released from mast cells and basophils. In addition, the present invention provides nucleic acid molecules encoding the fusion proteins, vectors and host cells for producing the fusion proteins, pharmaceutical compositions comprising the fusion proteins, and methods for ameliorating or reducing the risk of IgE-medicated allergic diseases.
... |
| Phytol derived immunoadjuvants and their use in vaccine formulations | 20060292163 | 20061228 |
| This invention relates to a novel immunoadjuvant, an adjuvant component, and vaccines containing the adjuvant component. The adjuvant includes phytol or a phytol derivative. The adjuvant component, when combined with a soluble or particulate antigen, provides a vaccine with an enhanced ability to induce both humoral and cytotoxic immune responses while displaying reduced toxicity and/or adverse side effects over vaccines that include the antigen but without the benefit of this adjuvant component.
... |
| Vaccine composition comprising flt3-ligand | 20060292166 | 20061228 |
| Flt3-ligand can be used to generate large numbers of dendritic cells from hematopoietic progenitor and stem cells. Flt3-ligand can be used to augment immune responses in vivo, and expand dendritic cells ex vivo. Such dendritic cells can then be used to present tumor, viral or other antigens to naive T cells, can be useful as vaccine adjuvants. When flt3-L is used and/or administered in combination with other reactive agents, e.g. CD40 binding proteins, 4-1BBL or antibodies reactive with 4-1BB, CD30 ligand antagonists, RANKL, and/or interferon alpha the combination further enhances immune responses and the effectiveness of vaccine adjuvants.
... |
| Therapeutic peptides and vaccines | 20060292167 | 20061228 |
| Compositions are disclosed that induce broadly HIV theraputic and vaccine inducing antibodies against diverse HIV clades and relate to the ability to identify HIV gp120-derived short peptide sequence immunogens and various therapeutic compositions made from the identified peptides which compose CCR5 binding sites. Also disclosed are methods of selecting peptide sequences that are likely candidates for drugs which will offer effective treatment in such areas as Alzheimer's disease, psoriasis, multiple sclerosis and other diseases associated with the human inflammatory cascade as well as related retroviruses such as HTLV-1, the cause of tropical spastic paraparesis.
... |
| Methylated heparin-binding hemagglutinin recombinant mycobacterial antigen, preparation method and immunogenic compositions comprising same | 20060292168 | 20061228 |
| The invention concerns a methylated immunogenic recombinant peptide sequence comprising mycobacterial heparin-binding hemagglutinin. The invention also concerns chemical and enzymatic methods for preparing such a sequence, the sequence being previously produced in a non-methylated recombinant form then methylated by post-translational modification. The invention further concerns recombinant tools, vectors and host cells for implementing post-translational enzymatic methylation of the recombinant HBHA. The invention finally concerns immunogenic compositions comprising methylated, native or recombinant HBHA, such compositions being useful for preparing vaccines against mycobacterial infections.
... |
| Vaccine composition against malaria | 20060292170 | 20061228 |
| A vaccine composition useful in the prevention or treatment of malaria comprises a plurality of malaria-derived antigens in combination with an adjuvant which is a preferential stimulator of TH1 cell response.
... |
| Dengue serotype 1 attenuated strain | 20060292172 | 20061228 |
| The invention relates to live attenuated VDV1 (VERO-Derived Dengue serotype 1 viruse) strains which have been derived from the wild-type dengue-1 strain 16007 by passaging on PDK and sanitization on Vero cells. The invention further relates to a vaccine composition which comprises a VDV1 strain.
... |
| Multibacterial vaccines and uses thereof | 20060292173 | 20061228 |
| The present invention provides methods for establishing standards for Gram-negative, Gram-positive, and mixed bacterial cultures. The present invention also provides methods for reproducing Gram-negative, Gram-positive, and mixed bacterial cultures. The present invention further provides methods for preparing multibacterial vaccines. Also provided are multibacterial vaccines prepared in accordance with these methods, and methods for treating and/or preventing disorders using these multibacterial vaccines. In addition, the present invention provides methods for predicting the efficacy of multibacterial vaccines, and methods for enhancing the efficacy of multibacterial vaccines.
... |
| In ovo vaccine against infectious bursal disease | 20060292176 | 20061228 |
| The present invention relates to a non pathogenic vaccine comprising a recombinant Infectious Bursal Disease virus that includes a recombinant Segment A, designated as rD78GLSNSΔ, that includes sequences from D78 and GLS strains and wherein the NS protein is not expressed.
... |
| Postweaning multisystemic wasting syndrome and porcine circovirus from pigs | 20060292177 | 20061228 |
| The cloning of a novel PCVII viral genome is described as is expression of proteins derived from the PCVII genome. These proteins can be used in vaccine compositions for the prevention and treatment of PCVII infections, as well as in diagnostic methods for determining the presence of PCVII infections in a vertebrate subject. Polynucleotides derived from the viral genome can be used as diagnostic primers and probes.
... |
| Vaccines for immunization against helicobacter | 20060292179 | 20061228 |
| The invention relates to the immunisation of pigs against Candidatus Helicobacter suis using antigens of species related to Candidatus Helicobacter suis.
... |
| Method for inducing a cell-mediated immune response and improved parenteral vaccine formulations thereof | 20060292181 | 20061228 |
| A method of inducing either a TH1 polarised immune response, a TH2 polarised immune response or a combined TH1 and TH2 response to an antigen and associated vaccine formulations are disclosed. A method is provided for inducing a polarised TH1 response by parenteral administration of microparticles sized such that at least 50% of the microparticles are less than 5 μm, the microparticles containing antigen entrapped or encapsulated by a biodegradable polymer. Additionally, a method is provided for inducing a polarised TH2 response by parenteral administration of nanoparticles sized such that at least 50% of the nanoparticles are less than 600 nm, the nanoparticles containing antigen entrapped or encapsulated by a biodegradable polymer. Vaccine formulations containing the B. pertussis antigens PTd, FHA or a combination of PTd... |
| Dendritic cell co-stimulatory molecules | 20060292593 | 20061228 |
| A novel costimulatory protein molecule, B7-DC, which is a member of the B7 family, is described as is DNA coding therefor and expression vectors comprising this DNA. B7-DC protein, fragments, fusion polypeptides/proteins and other functional derivatives, and transformed cells expressing B7-DC are useful in vaccine compositions and methods. Compositions and methods are disclosed for inducing potent T cell mediated responses that can be harnessed for anti-tumor and anti-viral immunity.
... |
| Antigen-presenting cell populations and their use as reagents for enhancing or reducing immune tolerance | 20060292618 | 20061228 |
| The present invention is based on the discovery antigen-presenting cells (APCs) may be generated to have predetermined levels of expression of the intracellular enzyme, indoleamine 2,3-dioxygenase (IDO). Because expression of high levels of IDO is correlated with a reduced ability to stimulate T cell responses and an enhanced ability to induce immunologic tolerance, APCs having high levels of IDO may be used to increase tolerance in the immune system, as for example in transplant therapy or treatment of autoimmune disorders. For example, APCs having high levels of IDO, and expressing or loaded with at least one antigen from a donor tissue may be used to increase tolerance of the recipient to the donor's tissue. Alternatively, APCs having reduced levels of IDO expression and expressing or loaded... |
| Methods for immunotherapy of cancer | 20060286074 | 20061221 |
| Provided are methods of generating an immune response to an antigen specifically associated with tumor vascular endothelial cells (TVECA). The method comprises administering to an individual an expression vector encoding the TVECA. The vector comprises a transcription unit encoding a secretable fusion protein, the fusion protein containing a TVECA and CD40 ligand. In other methods, administration of a fusion protein containing the TVECA and CD40 ligand is used to enhance the immune response above that obtained by vector administration alone. Further methods comprise the combination therapy using an expression vector encoding a secretable TVECA fusion protein and a tumor antigen vaccine.
... |
| Compositions and vaccines containing antigen(s) of cryptosporidium parvum and of another pathogen | 20060286109 | 20061221 |
| Combination compositions including C. parvum antigen(s) or epitope(s) of interest with at least one other antigen or epitope of interest from a pathogen that causes enteric infection and/or symptoms and/or recombinant(s) and/or vector(s) and/or plasmid(s) expressing such antigen(s) or epitope(s) of interest and administration of such compositions such as to pregnant mammals and/or newborn or young mammals, for instance, pregnant cows and/or calves such as within the first month of birth, are disclosed and claimed.
... |
| Bax-responsive genes for drug target identification in yeast and fungi | 20060286110 | 20061221 |
| The invention describes the use of nucleic acids and polypeptides which are involved in a pathway eventually leading to programmed cell death of yeast or fungi for the preparation of a medicament for treating diseases associated with yeast or fungi or for the treatment of proliferative disorders or for preventing apoptosis in certain diseases. Methods are provided to identify compounds which selectively modulate the expression or functionality of said polypeptides in the same or a parallel pathway. Also provided are compounds as well as pharmaceutical compositions, medicaments and vaccines. The invention also comprises new nucleic acid sequences, probes and primers derived thereof, expression vectors and host cells transformed with said vectors, polypeptides and antibodies raised against said polypeptides.
... |
| Synthetic gene encoding rhesus monkey carcinoembryonic antigen and uses thereof | 20060286114 | 20061221 |
| Synthetic polynucleotides encoding rhesus monkey carcinoembryonic antigen (CEA) are provided, the synthetic polynucleotides being condon-optimized for expression in a human cellular environment. The gene encoding CEA is commonly associated with the development of human carcinomas. The present invention provides compositions and methods to elicit or enhance immunity to the protein product expressed by the CEA tumor-associated antigen, wherein aberrant CEA expression is associated with a carcinoma or its development. This invention specifically provides adenovial vector and plasmid constructs carrying codon-optimed rhesus monkey CEA and discloses their use in vaccines and pharmaceutical compositions for preventing and treating cancer.
... |
| Preventive cancer vaccine based on brother of regulator of imprinted sites molecule | 20060286115 | 20061221 |
| Polynucleotides encoding a nonfunctional mutant form of the Brother of Regulator of Imprinted Sites (BORIS) molecule, nonfunctional mutated BORIS protein, polypeptide or peptide and modified protein forms of BORIS are described. These molecules are used as a therapeutic vaccine against cancer.
... |
| Lawsonia intracllularis subunit vaccine | 20060286118 | 20061221 |
| The present invention relates to nucleic acid sequences encoding novel Lawsonia intracelluaris proteins. It furthermore relates to DNA fragments, recombinant DNA molecules and live recombinant carriers comprising these sequences. Also it relates to host cells comprising such nucleic acid sequences, DNA fragments, recombinant DNA molecules and live recombinant carriers. Moreover, the invention relates to proteins encoded by these nucleotide sequences and to their use for the manufacturing of vaccines. The invention also relates to vaccines for combating Lawsonia intracellulairs infections and methods for the preparation thereof. Finally the invention relates to diagnostic tests for the detection of Lawsonia intracellularis DNA, the detection of Lawsonia intracellularis antigens and of antibodies against Lawsonia intracellularis.
... |
| Adenoviral vector-based vaccines | 20060286121 | 20061221 |
| The invention provides a method of inducing an immune response in a mammal. The method comprises administering to the mammal a non-subgroup C adenoviral vector comprising an adenoviral fiber protein having an amino acid sequence comprising about 80% or more identity to an amino acid sequence encoding a subgroup C adenoviral fiber protein. The adenoviral vector further comprises a nucleic acid sequence encoding an antigen which is expressed in the mammal to induce an immune response. The invention further comprises a method of producing an adenoviral vector, and a composition comprising a serotype 41 or a serotype 35 adenoviral vector and a carrier. The invention also provides an adenoviral vector comprising a nucleic acid sequence encoding an adenoviral pIX protein operably linked to a heterologous expression... |
| prrs vaccines | 20060286123 | 20061221 |
| The present invention is related to improved modified live PRRS vaccines of European genotype and new PRRSV strains which can be used for the manufacture of such vaccines.
... |
| Vaccine compositions and methods of treating coronavirus infection | 20060286124 | 20061221 |
| The present disclosure relates to compositions and methods for treating or preventing coronavirus infections. For example, compositions are provided that comprise a coronavirus S protein or N protein, fragment, or variant thereof, capable of eliciting a protective humoral and/or cell-mediated immune response, which compositions are useful for treating or preventing infection by coronavirus, such as the causative agent of SARS. Also, coronavirus S protein and N protein immunogen compositions are provided that include an adjuvant, such as Proteosome or Protollin, which may be used for treating or preventing infection caused by a coronavirus, such as a SARS coronavirus.
... |
| Adjuvant combinations of liposomes and mycobacteriaial lipids for immunization compositions and vaccines | 20060286128 | 20061221 |
| The present invention provides a vaccine adjuvant consisting of a combination of a surfactant i.e. dimethyldioctadecylammonium-bromide/chloride (DDA) and a lipid extract from The present invention provides a vaccine adjuvant consisting of a combination of a surfactant i.e. dimethyldeoctadecylammonium-bromide/chloride (DDA) and a lipid extract from <The present invention provides a vaccine adjuvant consisting of a combination of a surfactant i.e. dimethyldeoctadecylammonium-bromide/chloride (DDA) and a lipid extract from Mycobacterium bovis. The present invention provides a vaccine adjuvant consisting of a combination of a surfactant i.e. dimethyldeoctadecylammonium-bromide/chloride (DDA) and a lipid extract from Mycobacterium bovis<The present invention provides a vaccine adjuvant consisting of a combination of a surfactant i.e. dimethyldeoctadecylammonium-bromide/chloride (DDA) and a lipid extract from Mycobacterium bovis BCG The present invention provides a vaccine adjuvant consisting of a... |
| Rt-pcr detection for differential diagnosis of field isolates or lapinized vaccine strain of classical swine fever virus (csfv) in samples | 20060286551 | 20061221 |
| The present invention provides a rapid RT-PCR detection method and a diagnostic kit for differentiating field isolates of classical swine fever virus (CSFV) from lapinized CSF vaccine viruses in samples. In order to detecting different genotypes of CSF virus, this invention uses a pair (or pairs) of CSF virus specific primers designed from the conserved sequences within the 3′-untranslated region of CSFV which contains an insertion of 12˜13 nucleotides (poly T) in the region of the lapinized CSF vaccine virus, in comparison with the corresponding region of field isolates of CSFV. By the RT-PCR or the RT-PCR followed by a nest-PCR, field isolates of CSFV and lapinized CSF vaccine viruses in samples could be detected directly and quickly and/or differentiated in electrophoresis without further enzymatic digestion... |
| Postweaning multisystemic wasting syndrome and porcine circovirus from pigs | 20060286642 | 20061221 |
| The cloning of a novel PCVII viral genome is described as is expression of proteins derived from the PCVII genome. These proteins can be used in vaccine compositions for the prevention and treatment of PCVII infections, as well as in diagnostic methods for determining the presence of PCVII infections in a vertebrate subject. Polynucleotides derived from the viral genome can be used as diagnostic primers and probes.
... |
| Methods and compositions for inducing antigen-specific immune responses | 20060287263 | 20061221 |
| Vaccine compositions comprising (a) an oligonucleotide, (b) and immune stimulating complex and (c) an antigen induce a strong interferon-gamma immune response. Both oligonucleotides containing immune stimulatory motifs and oligonucleotides lacking immune stimulatory motifs contribute to an interferon-gamma response when administered with an immune stimulating complex.
... |
| Method for terminal sterilization of transdermal delivery devices | 20060280644 | 20061214 |
| A method and system for providing a terminally sterilized transdermal influenza vaccine delivery device. A microprojection member having a plurality of stratum corneum-piercing microprojections is coated with an influenza vaccine-formulation and exposed to sufficient radiation to sterilize the microprojection member while retaining sufficient potency of the influenza vaccine. Preferably, the microprojection member is sealed in packaging, such as a foil pouch. Also preferably, a retainer ring and adhesive are included within the packaging. The sterilizing radiation can be gamma radiation or e-beam, preferably delivered in a dose in the range of approximately 7-21 kGy. Also preferably, the irradiation is performed from −78.5-25° C. In preferred embodiments, the radiation is delivered at a rate greater than 3.0 kGy/hr.
... |
